|
Technology Available for Licensing
NOVEL SALIVA TEST for EARLY DIAGNOSIS of CANCER: based upon the Concentration of Proteonic Cancer Markers/Antigen. Currently, cancer is diagnosed by computerized tomography (CT) scan after the tumor is formed. Proteonic cancer markers/antigen (PCMs) specific to breast, colon, liver and ovary were identified, and were isolated from the respective lysate of transformed cells, by differential centrifugation. Polyclonal antibodies were generated against the PCMs for breast, colon, liver and ovary individually and combination thereof.. At Ophidia Products, Inc we have developed a saliva test to detect early stage of cancer. A patent entitled, “Novel Saliva Test for Early Diagnosis of Different Types of Cancers” (Patent pending). Saliva specimens from normal people were assayed by enzyme-linked immunosorbent assay (ELISA) for anti-mixture of PCMs, and breast, colon, liver and ovary PCM individually. It was revealed that cancer antigen was detectable in saliva from normal people and the ELISA titer/100 µl ranged from 1:300 to 1;1600. Out of 50 normal specimens tested, ELISA titer/100 µl, was higher than 1:1000 in seven specimens, meaning 14 % of the population is prone to develop tumor/cancer. Those seven specimens were assayed for individual PCM for breast, colon, liver and ovary. It was revealed that most of the specimens showed high titer for one type of cancer except one specimen showed equally high titers for two types of cancers, colon and ovary. It is known that cancer incidents increase by age. Saliva specimens from young boys raging from five to eight years showed lowest ELISA titers for total PCMs. This proves the known fact that cancer and thus the presence of PCMs increase exponentially by aging. We have also found the reduction in PCMs concentration in saliva of cancer patients who have under gone chemotherapy. These findings emphasis that the saliva test is specific for diagnosis of cancer based upon the concentration of PCMs. The study of Tamoxifen and Raoxifene (STAR) is supported by the National Cancer Institute (NCI) for the prevention of breast cancer. STAR began in 1999 and has enrolled more than 16,300 of its planned 19,000 participants. This study includes post-menopausal women age 35 or older. It is estimated that 12.5 % of women will have breast cancer during their lifetime. The study puts 87.5 % women who will nor develop breast cancer are subjected to the treatment with Tamoxifen or raloxifene. Every chemotherapy has adverse side effects in some people, therefore some of these women will have adverse effects only for the sake of treatment rather than preventing cancer. Thrust of the study is to show the difference in efficacy between Tamoxifen and raloxifene Novel saliva tests have following features:
|